TL;DR
Compounding pharmacy insurance sizing depends on 503A vs 503B scope, sterile vs non-sterile workflow, state license count, and ownership structure. The single highest-risk renewal verification in 2026 is whether the endorsement schedule silently added a non-FDA-approved drug exclusion - if your GLP-1 revenue line is uninsured, you should know before signing the renewal.
Compounding Pharmacies · Texas
Texas compounding pharmacies operate at the intersection of state board enforcement, USP 797/800 compliance, PBM network credentialing, and increasingly aggressive carrier endorsement schedules - including GLP-1 exclusions added without prominent disclosure at renewal.
We help 503A sterile and non-sterile compounders rebuild programs around druggist professional liability with adequate scope, products coverage that does not silently exclude their lines, and property coverage that responds to sterile-suite and hazardous-drug exposures.
Problem 01 · USP 797 compliance
Carriers underwriting sterile compounding require current USP 797 documentation as a condition of binding. The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; pharmacies that updated SOPs to comply have a smoother renewal experience than those that did not.
State board of pharmacy inspections also feed into underwriting. Form 483 observations, warning letters, and recent enforcement actions all factor into renewal pricing and availability.
Problem 02 · GLP-1 exclusions
Several specialty pharmacy carriers added exclusions for compounded versions of FDA-approved branded drugs (semaglutide, tirzepatide) starting in 2025-2026, often without prominent disclosure at renewal. A pharmacy compounding GLP-1s under a policy with this exclusion has uninsured products liability for that revenue line.
See the dedicated GLP-1 page for the full landscape.
Problem 03 · PBM network status
PBM network agreements (Express Scripts, CVS Caremark, OptumRx) require druggist professional liability and general liability minimums plus current COI on file. A 30-day notice of cancellation lapse can trigger silent network removal - dispensing continues but claims start getting denied, with the pharmacy often discovering the lapse only after weeks of accumulated denied revenue.
Reinstatement after administrative lapse is sometimes possible. Reinstatement after a claims-driven termination is much harder. Coverage discipline at renewal is the cheapest defense.
Problem 01 · Endorsement schedule audit
Specialty pharmacy carriers added non-FDA-approved drug exclusions to renewal endorsement schedules across 2025 and 2026 - sometimes mid-policy, sometimes at renewal without prominent disclosure. The most common silent additions: GLP-1 exclusions, non-FDA-approved drug exclusions, weight-loss drug exclusions.
The verification is mechanical but tedious. Read every renewal endorsement, search for the exclusion keywords, document the result. We do this for clients as a standard quarterly check; operators handling it in-house should set a calendar reminder before each renewal.
Problem 02 · Druggist professional liability scope
Druggist professional liability covers dispensing errors, compounding errors, BUD miscalculation, mislabeling, and counseling failures. Standard policies vary materially on whether sterile compounding errors, hazardous-drug handling violations, or 503B-adjacent activities fall within scope.
The fix is verifying the policy explicitly addresses your workflow scope rather than relying on default druggist PL language. Specialty compounders with high-risk product lines need $3M+ per incident as a floor.
Problem 03 · USP 797/800 property exposure
USP 797 sterile compounding suites and USP 800 hazardous-drug handling areas create property exposures that standard pharmacy property policies do not address: validation losses after a covered event, sterility re-validation costs, environmental monitoring failures, and HEPA filtration system claims.
Property programs should include explicit validation loss extension and BUD-extension business interruption coverage. Operators discovering this gap at first claim are usually 90 days into a stop-compounding situation.
Problem 04 · State board defense
State board of pharmacy enforcement - inspections, deficiency citations, license suspensions - is the most frequent claim category for compounding pharmacies. Most generalist programs include limited regulatory defense; specialty programs include dedicated state board defense scope.
The dollar amounts per proceeding are modest individually, but the cumulative drain and the license-at-risk severity make dedicated coverage load-bearing. Operators in active enforcement environments (Texas, California, Florida) typically place dedicated state board defense.
Carrier access
Generalist pharmacy carriers will write a 503A compounder and silently add GLP-1 exclusions at renewal. The placement looks fine on the COI. The GLP-1 revenue line is uninsured.
Our placements run through carriers with dedicated compounding pharmacy underwriting and active appetite for GLP-1 and high-risk product lines. We know which markets still write semaglutide and tirzepatide compounders vs which exited the segment in 2025-2026.
Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.
Pricing
Premium ranges for 503A sterile and non-sterile compounders, the factors that drive cost, and sample programs by workflow and state.
Frequently asked
Druggist professional liability, products liability, general liability, property (with sterile-suite or hazardous-drug peril if applicable), cyber for HIPAA exposure, and crime/fidelity. Sterile compounders need higher products limits.
Carriers underwriting sterile compounding require current USP 797 documentation as a condition. Clean inspection history can earn credit; lapses trigger non-renewal or restrictive endorsements.
Maybe not - many specialty pharmacy carriers added GLP-1 exclusions in 2025-2026. Read the endorsement schedule carefully. If you compound GLP-1s, the exclusion is often the most important line in the policy.
503A patient-specific compounding uses a pharmacy-classed program. 503B outsourcing-facility status requires manufacturer-classed coverage with cGMP property, higher products limits, and FDA-specific recall language.
Specialty markets typically need 2-4 weeks for sterile/503B accounts. Underwriting requires USP 797 documentation, current state board inspection history, and 5 years of loss runs. Plan ahead of renewal.
Yes. Pharmacies hold significant PHI under HIPAA, and Texas HB300 adds state-level requirements. A standalone cyber policy with HIPAA notification expense coverage is standard.
Next steps
Five questions about your operation. Get a single named coverage gap most likely to surface at first claim - including GLP-1 exclusion checks.
OpenPaste 3 customer contract indemnity clauses. Get a verdict on the risk transfer architecture.
OpenFive 503B coverage strategies - relevant if you are considering the 503B regulatory path.
OpenFive compounding pharmacy program structures by 503A vs 503B scope, sterile vs non-sterile, multi-state, and PE-backed platform.
OpenAuthoritative references
The sterile-compounding standard state boards enforce - revised 2023, effective November 2023.
Hazardous-drug handling requirements - drives workers comp and pollution exposures.
FDA scope of 503A traditional pharmacy compounding under FD&C Act section 503A.
Texas-specific compounding rules - relevant to most LSL compounding clients.
NABP accreditation drives PBM and payor credentialing requirements.
Why operators choose this practice
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Related deep-dives
Free coverage review
No marketing sequences, no list rental. Half-hour MSA reads are the standard.